Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 4/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 4/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19343832 | 0.87 | ABL1 (0.56) | CYP1A2ABL1RIN1NR2F2GALR3 | |
| SCHEMBL25004 | 0.87 | ABL1 (0.56) | CYP1A2ABL1RIN1NR2F2GALR3 | |
| SCHEMBL19146448 | 0.86 | CYP1A2 (0.48) | CYP1A2ABL1RIN1NR2F2GALR3 | |
| SCHEMBL12652414 | 0.85 | UBA6 (0.47) | CYP1A2ABL1RIN1NR2F2GALR3 | |
| SCHEMBL19146385 | 0.84 | CYP1A2 (0.44) | CYP1A2ABL1RIN1NR2F2GALR3 | |
| SCHEMBL19146239 | 0.84 | P2RY12 (0.44) | CYP1A2ABL1RIN1NR2F2GALR3 | |
| SCHEMBL22907578 | 0.83 | SLC29A1 (0.42) | CYP1A2 | |
| SCHEMBL21540034 | 0.83 | P2RY12 (0.44) | CYP1A2ABL1RIN1NR2F2GALR3 | |
| SCHEMBL21726069 | 0.82 | P2RY12 (0.55) | P2RY12 | |
| SCHEMBL20792252 | 0.81 | ADORA3 (0.44) | NPC1RAB9ASMN1; SMN2BMPR1BPRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | CYP1A2 4630/4885ABL1 1052/4885RIN1 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.